The shares of the pharmaceutical company gained up to 8 percent after the company received Marketing Authorization for Pemetrexed 500mg in the Philippines.
With a market capitalization of Rs 447.73 crore, the shares of Venus Remedies Limited were trading at Rs 334.95 per share, increasing around 4.25 percent as compared to the previous closing price of Rs 323.15 apiece.
Reason for rise:-
The company shares have seen positive movement after Venus Remedies Limited announced the approval of Pemetrexed 500mg, a chemotherapeutic drug often used in the treatment of lung cancer and rnesothelioma, in the Philippines. This permission is a significant step forward in the company’s efforts to increase its footprint in the fast-growing Southeast Asian pharmaceutical sector.
Financial Performance:-
Looking forward to the company’s financial performance, revenue dipped slightly from Rs 167.72 crore in Q2FY24 to Rs 167.45 crore in Q2Y25. During the same period, net profit plummeted by 68 percent, from Rs 9.94 crore to Rs 3.51 crore.
Market expansion:-
Venus Remedies plans to increase its presence in government institutions across India, capitalizing on the demand for antimicrobial products. Additionally, the company aims to expand its global reach, targeting a presence in 100 countries by 2025.
New Development:-
Venus Remedies focuses on developing innovative therapies targeting Antimicrobial Resistance (AMR) due to its global health impact. Additionally, the company plans to enter the consumer healthcare market, launching disruptive products in pain management, gastroenterology, and vitamins over the next five years.
Ratio analysis:-
The company’s critical ratios show that the return on equity increased from 5.77 percent in FY22-23 to 5.84 percent in FY23-24, while the return on capital employed increased from 7.37 percent to 8.17 percent. The net profit margin (NPM) for fiscal year 23-24 is 4.73 percent.
Shareholding pattern:-
In the company’s recent shareholding pattern, the Promoters of the company own 41.76 percent while Retail shareholders own a 57.06 percent stake in the company and domestic Institutional Investors own a 1.18 percent stake.
Company Profile:-
VSR is a leading manufacturer of meropenem antibiotics and an emerging player in AMR drugs in India. The company provides a diverse range of pharmaceutical products for various therapeutic areas, including anti-infectives, antimicrobial resistance, oncology, neurology, pain management, skin and wound care.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
